Literature DB >> 17050201

Synergistic effect of arsenic trioxide and flt3 inhibition on cells with flt3 internal tandem duplication.

Shinichiro Takahashi1, Hideo Harigae, Hisayuki Yokoyama, Izumi Ishikawa, Shouri Abe, Masue Imaizumi, Takeshi Sasaki, Mitsuo Kaku.   

Abstract

Flt3 internal tandem duplication (Flt3-ITD) is a prevalent mutation in acute myeloid leukemia (AML). Flt3-ITD constitutively activates various signaling pathways, including a mitogen-activated protein kinase kinase (MEK)/extracellular signal-regulated kinase (ERK) pathway. Arsenic trioxide (ATO) and MEK inhibition were recently reported to interact synergistically to induce apoptosis in AML cells. In this study, we aimed to clarify whether ATO and Flt3 inhibition would be a more specific and efficient therapy for Flt3-ITD cells. We demonstrate that the combination of ATO and an Flt3 inhibitor, AG1296, profoundly inhibits the growth of Flt3-ITD cells and induces their apoptosis. We further revealed that this combined treatment potently inhibits the ERK activity that might be responsible for cell growth. Moreover, using the Chou-Talalay method, we observed a synergistic growth-inhibitory effect for ATO and AG1296 in Flt3-ITD cells (BaF3-Flt3-ITD, MV4-11, and PL-21 cells), but not in Flt3 wild-type cells (RS4-11 and NB4 cells), for almost all dose ranges tested. Our results provide an experimental basis for a specific and efficient therapy for Flt3-ITD cells that involves combined treatment with Flt3 inhibitors and ATO.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17050201     DOI: 10.1532/IJH97.06076

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  39 in total

1.  The MEK inhibitor, PD98059, reduces survival but does not block acute myeloid leukemia blast maturation in vitro.

Authors:  P Baines; J Fisher; L Truran; E Davies; M Hallett; T Hoy; A K Burnett
Journal:  Eur J Haematol       Date:  2000-04       Impact factor: 2.997

2.  Cloning of a coproporphyrinogen oxidase promoter regulatory element binding protein.

Authors:  S Takahashi; K Furuyama; A Kobayashi; S Taketani; H Harigae; M Yamamoto; K Igarashi; T Sasaki; N Hayashi
Journal:  Biochem Biophys Res Commun       Date:  2000-07-05       Impact factor: 3.575

3.  Transient poly(ADP-ribosyl)ation of nuclear proteins and role of poly(ADP-ribose) polymerase in the early stages of apoptosis.

Authors:  C M Simbulan-Rosenthal; D S Rosenthal; S Iyer; A H Boulares; M E Smulson
Journal:  J Biol Chem       Date:  1998-05-29       Impact factor: 5.157

4.  Inverse correlation between Flt3 and PU.1 expression in acute myeloblastic leukemias.

Authors:  Mitsue Inomata; Shinichiro Takahashi; Hideo Harigae; Junichi Kameoka; Mitsuo Kaku; Takeshi Sasaki
Journal:  Leuk Res       Date:  2005-11-04       Impact factor: 3.156

5.  The stress inducer arsenite activates mitogen-activated protein kinases extracellular signal-regulated kinases 1 and 2 via a MAPK kinase 6/p38-dependent pathway.

Authors:  S Ludwig; A Hoffmeyer; M Goebeler; K Kilian; H Häfner; B Neufeld; J Han; U R Rapp
Journal:  J Biol Chem       Date:  1998-01-23       Impact factor: 5.157

6.  Human leukemias with mutated FLT3 kinase are synergistically sensitive to FLT3 and Hsp90 inhibitors: the key role of the STAT5 signal transduction pathway.

Authors:  Q Yao; R Nishiuchi; T Kitamura; J H Kersey
Journal:  Leukemia       Date:  2005-09       Impact factor: 11.528

7.  CHIR-258: a potent inhibitor of FLT3 kinase in experimental tumor xenograft models of human acute myelogenous leukemia.

Authors:  Daniel E Lopes de Menezes; Jing Peng; Evelyn N Garrett; Sharianne G Louie; Sang H Lee; Marion Wiesmann; Yan Tang; Lee Shephard; Cheryl Goldbeck; Yoko Oei; Helen Ye; Sharon L Aukerman; Carla Heise
Journal:  Clin Cancer Res       Date:  2005-07-15       Impact factor: 12.531

8.  Inhibition of the transforming activity of FLT3 internal tandem duplication mutants from AML patients by a tyrosine kinase inhibitor.

Authors:  K-F Tse; J Allebach; M Levis; B D Smith; F D Bohmer; D Small
Journal:  Leukemia       Date:  2002-10       Impact factor: 11.528

9.  NB4, a maturation inducible cell line with t(15;17) marker isolated from a human acute promyelocytic leukemia (M3).

Authors:  M Lanotte; V Martin-Thouvenin; S Najman; P Balerini; F Valensi; R Berger
Journal:  Blood       Date:  1991-03-01       Impact factor: 22.113

10.  MEK1 inhibition sensitizes primary acute myelogenous leukemia to arsenic trioxide-induced apoptosis.

Authors:  Paolo Lunghi; Antonio Costanzo; Luigi Salvatore; Nelida Noguera; Laura Mazzera; Antonio Tabilio; Francesco Lo-Coco; Massimo Levrero; Antonio Bonati
Journal:  Blood       Date:  2006-02-07       Impact factor: 22.113

View more
  5 in total

Review 1.  Downstream molecular pathways of FLT3 in the pathogenesis of acute myeloid leukemia: biology and therapeutic implications.

Authors:  Shinichiro Takahashi
Journal:  J Hematol Oncol       Date:  2011-04-01       Impact factor: 17.388

Review 2.  Mutations of FLT3 receptor affect its surface glycosylation, intracellular localization, and downstream signaling.

Authors:  Shinichiro Takahashi
Journal:  Leuk Res Rep       Date:  2019-11-27

3.  Arsenic Trioxide and Venetoclax Synergize against AML Progenitors by ROS Induction and Inhibition of Nrf2 Activation.

Authors:  Dinh Hoa Hoang; Ralf Buettner; Melissa Valerio; Lucy Ghoda; Bin Zhang; Ya-Huei Kuo; Steven T Rosen; John Burnett; Guido Marcucci; Vinod Pullarkat; Le Xuan Truong Nguyen
Journal:  Int J Mol Sci       Date:  2022-06-12       Impact factor: 6.208

4.  Arsenic trioxide and triptolide synergistically induce apoptosis in the SKM‑1 human myelodysplastic syndrome cell line.

Authors:  Hai-Ying Hua; Hua-Qiang Gao; Ai-Ning Sun; Jian-Nong Cen; Li-Li Wu
Journal:  Mol Med Rep       Date:  2016-09-26       Impact factor: 2.952

5.  Combination of ATO with FLT3 TKIs eliminates FLT3/ITD+ leukemia cells through reduced expression of FLT3.

Authors:  Kozo Nagai; Lihong Hou; Li Li; Bao Nguyen; Tessa Seale; Courtney Shirley; Hayley Ma; Mark Levis; Gabriel Ghiaur; Amy Duffield; Donald Small
Journal:  Oncotarget       Date:  2018-08-31
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.